nefazodone has been researched along with Panic Disorder in 10 studies
nefazodone: may be useful as an opiate adjunct
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten patients meeting DSM-IV criteria for non-comorbid panic disorder or panic disorder with agoraphobia were treated in a 12-week open-label, flexible dosage trial of nefazodone." | 9.09 | Pilot open-label study of nefazodone in panic disorder. ( Bystritsky, A; Rosen, R; Suri, R; Vapnik, T, 1999) |
| "Fifteen patients with panic disorder participated in a 12-week treatment trial with open-label nefazodone." | 9.09 | Efficacy of open-label nefazodone treatment in patients with panic disorder. ( Coplan, JD; de Jesus, M; Gorman, JM; Martinez, JM; Papp, LA, 2000) |
| "Nefazodone is a recently marketed compound with demonstrated efficacy in major depression." | 9.08 | An open-label trial of nefazodone in high comorbidity panic disorder. ( DeMartinis, NA; Rickels, K; Schweizer, E, 1996) |
| "Ten patients meeting DSM-IV criteria for non-comorbid panic disorder or panic disorder with agoraphobia were treated in a 12-week open-label, flexible dosage trial of nefazodone." | 5.09 | Pilot open-label study of nefazodone in panic disorder. ( Bystritsky, A; Rosen, R; Suri, R; Vapnik, T, 1999) |
| "Fifteen patients with panic disorder participated in a 12-week treatment trial with open-label nefazodone." | 5.09 | Efficacy of open-label nefazodone treatment in patients with panic disorder. ( Coplan, JD; de Jesus, M; Gorman, JM; Martinez, JM; Papp, LA, 2000) |
| "Nefazodone is a recently marketed compound with demonstrated efficacy in major depression." | 5.08 | An open-label trial of nefazodone in high comorbidity panic disorder. ( DeMartinis, NA; Rickels, K; Schweizer, E, 1996) |
| "Lifetime psychiatric illness is also common in women with PMDD, and although mood disorders predominate, past histories of anxiety disorders are also common, further suggesting an association between PMDD and anxiety disorders." | 2.40 | Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? ( Yonkers, KA, 1997) |
| "The management of the patient's withdrawal symptoms is described." | 1.31 | Pharmacokinetically induced benzodiazepine withdrawal. ( Ninan, PT, 2001) |
| "First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months." | 1.31 | [Familial myoclonus-dystonia syndrome associated with panic attacks]. ( Hartmann, E; Koenig, E; Müller, F; Scheidtmann, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ninan, PT | 1 |
| DeMartinis, NA | 1 |
| Schweizer, E | 1 |
| Rickels, K | 1 |
| Yonkers, KA | 1 |
| Benazzi, F | 1 |
| Berigan, TR | 1 |
| Casas, A | 1 |
| Harazin, J | 1 |
| Bystritsky, A | 1 |
| Rosen, R | 1 |
| Suri, R | 1 |
| Vapnik, T | 1 |
| Papp, LA | 1 |
| Coplan, JD | 1 |
| Martinez, JM | 1 |
| de Jesus, M | 1 |
| Gorman, JM | 1 |
| Scheidtmann, K | 1 |
| Müller, F | 1 |
| Hartmann, E | 1 |
| Koenig, E | 1 |
| Montejo, AL | 1 |
| Llorca, G | 1 |
| Izquierdo, JA | 1 |
| Rico-Villademoros, F | 1 |
| Ströhle, A | 1 |
| Ehrenthal, HD | 1 |
1 review available for nefazodone and Panic Disorder
| Article | Year |
|---|---|
Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders?
Topics: 1-Naphthylamine; Adult; Age of Onset; Anxiety; Anxiety Disorders; Buspirone; Carbon Dioxide; Comorbi | 1997 |
4 trials available for nefazodone and Panic Disorder
| Article | Year |
|---|---|
An open-label trial of nefazodone in high comorbidity panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depression; Depress | 1996 |
Pilot open-label study of nefazodone in panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Humans; Male; Middle Aged; Panic Disorder; | 1999 |
Efficacy of open-label nefazodone treatment in patients with panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Humans; Male; Middle Aged; Panic Disorder; | 2000 |
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Depressive Disorder; Female; Humans | 2001 |
5 other studies available for nefazodone and Panic Disorder
| Article | Year |
|---|---|
Pharmacokinetically induced benzodiazepine withdrawal.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Inter | 2001 |
Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy.
Topics: Adult; Antidepressive Agents; Clonazepam; Cyclohexanols; Depressive Disorder; Desipramine; Drug Ther | 1997 |
Nefazodone and the treatment of panic.
Topics: Adult; Agoraphobia; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined | 1998 |
[Familial myoclonus-dystonia syndrome associated with panic attacks].
Topics: Adult; Chromosome Aberrations; Chromosome Disorders; Dystonic Disorders; Female; Genes, Dominant; Hu | 2000 |
Nefazodone may increase anxiety in panic disorder.
Topics: Adult; Anxiety; Humans; Male; Panic Disorder; Piperazines; Triazoles | 2002 |